EWTX EWTX

$39.34 ▼ -4.42% ($-1.82)

⬇️ Below Yest. Low

Open $41.59

Prev Close $41.16

Day Range $38.57 – $41.99

📋 Company Profile

Employees	127
Listed	2021-03-26
Shares Out.	108,604,129
Website	edgewisetx.com ↗
Revenue	$0
Gross Profit	$0
Net Income	-$57.3M
Free Cash Flow	-$158.8M
Total Assets	$479.7M
Total Liabilities	$31.6M
Equity	$448.1M

About EWTX

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.

EWTX is a publicly traded company under the ticker symbol EWTX. Quotes and metrics shown here are sourced from public market data and refreshed regularly.